PSMB9 and non-Hodgkin lymphoma: LMP1/LMP2- or LMP2-specific CTLs administered to 50 patients with EBV-related NHL or HL showed promising results in patients with risk or refractory/relapsed disease, with most achieving a 2-year event-free survival.